Literature DB >> 9952023

Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner.

M Nieda1, A Nicol, Y Koezuka, A Kikuchi, T Takahashi, H Nakamura, H Furukawa, T Yabe, Y Ishikawa, K Tadokoro, T Juji.   

Abstract

Vact14NK(natural killer) T cells play an important role in controlling tumors or in preventing autoimmunity in the murine system. Valpha24NKT cells, the human counterpart of Valpha14NKT cells, may contribute to controlling the progression of autoimmune diseases in humans. These findings show the possibility that ligand(s) for these NKT cells can control the above-mentioned pathological conditions. Specific glycolipids such as alpha-galactosylceramide (alpha-GalCer) and alpha-glucosylceramide (alpha-GlcCer) have been identified as ligand(s) recognized by murine Valpha14NKT cells in a CD1d-restricted manner, but it remains unclear whether these glycolipids are ligand(s) for Valpha24NKT cells in humans. To determine whether alpha-glycosylceramide is presented by CD1d molecules in humans, we initially established a Valpha24NKT cell line specific for alpha-glycosylceramide using dendritic cell (DC) like cells from normal peripheral blood mononuclear cells (PBMC) in an autologous mixed leukocyte reaction (auto-MLR) system, and characterized the Valpha24NKT cell line. The Valpha24NKT cells were CD3+ CD4-CD8-Valpha24+Vbeta11+NKRP1A+ and specifically proliferated in response to alpha-glycosylceramide in CD1d-restricted and Valpha24TCR-mediated manner. The phenotypic and functional similarities between murine Valpha14NKT cells and human Valpha24NKT cells suggest that Valpha24NKT cells may play an important role in controlling tumors or in preventing autoimmunity as observed with Valpha14NKT cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9952023     DOI: 10.1016/s0198-8859(98)00100-1

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  23 in total

1.  Effects of alpha-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Valpha24+ Vbeta11+ T cells.

Authors:  H J Van Der Vliet; N Nishi; Y Koezuka; M A Peyrat; B M Von Blomberg; A J Van Den Eertwegh; H M Pinedo; G Giaccone; R J Scheper
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

2.  CD1d ligation on human monocytes directly signals rapid NF-kappaB activation and production of bioactive IL-12.

Authors:  Simon C Yue; Angela Shaulov; Ruojie Wang; Steven P Balk; Mark A Exley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-09       Impact factor: 11.205

3.  Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography.

Authors:  A Karadimitris; S Gadola; M Altamirano; D Brown; A Woolfson; P Klenerman; J L Chen; Y Koezuka; I A Roberts; D A Price; G Dusheiko; C Milstein; A Fersht; L Luzzatto; V Cerundolo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

4.  Dendritic cells rapidly undergo apoptosis in vitro following culture with activated CD4+ Valpha24 natural killer T cells expressing CD40L.

Authors:  M Nieda; A Kikuchi; A nicol; Y Koezuka; Y Ando; S Ishihara; N Lapteva; T Yabe; K Tokunaga; K Tadokoro; T Juji
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

5.  Expression of CD1d in human scalp skin and hair follicles: hair cycle related alterations.

Authors:  M A Adly; M A Adley; H A Assaf; M Hussein
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

6.  Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.

Authors:  A Nicol; M Nieda; Y Koezuka; S Porcelli; K Suzuki; K Tadokoro; S Durrant; T Juji
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

7.  The CD1d natural killer T-cell antigen presentation pathway is highly conserved between humans and rhesus macaques.

Authors:  Koichi Kashiwase; Akiko Kikuchi; Yoshitaka Ando; Andrew Nicol; Steven A Porcelli; Katsushi Tokunaga; Mitsuhiro Omine; Masahiro Satake; Takeo Juji; Mie Nieda; Yasuhiko Koezuka
Journal:  Immunogenetics       Date:  2003-02-06       Impact factor: 2.846

Review 8.  Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants.

Authors:  Sungjune Kim; Saif Lalani; Vrajesh V Parekh; Lan Wu; Luc Van Kaer
Journal:  Expert Rev Vaccines       Date:  2008-12       Impact factor: 5.217

9.  Regulation of HLA-DR and co-stimulatory molecule expression on natural killer T cells by granulocyte-macrophage colony-stimulating factor.

Authors:  Kamal U Saikh; Teri Kissner; Robert G Ulrich
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

Review 10.  Human invariant natural killer T cells: implications for immunotherapy.

Authors:  Tsuyoshi Takahashi; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2009-07-29       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.